Joline Roze

Joline Roze


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
JRJoline Roze
Joline Roze
HMHannah S. van Meurs
Hannah S. van Meurs
GMGlen R. Monroe
Glen R. Monroe
WVWouter B. Veldhuis
Wouter B. Veldhuis
LLLuc R.C.W. van Lonkhuijzen
Luc R.C.W. van Lonkhuijzen
ABArthur J.A.T. Braat
Arthur J.A.T. Braat
Https://doi.org/10.18632/oncotarget.27925 Joline F. Roze, Hannah S. van Meurs, Glen R. Monroe, Wouter B. Veldhuis, Luc R.C.W. van Lonkhuijzen, Roel J. Bennink, Jolijn W. Groeneweg, Petronella O....

1 August 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
JGJolijn Groeneweg
Jolijn Groeneweg
JRJoline Roze
Joline Roze
WVWouter Veldhuis
Wouter Veldhuis
JRJelle Ruurda
Jelle Ruurda
CGCornelis Gijsbertus Gerestein
Cornelis Gijsbertus Gerestein
RZRonald Zweemer
Ronald Zweemer
• In this pilot study, the use of robotic debulking surgery for recurrent granulosa cell tumors was retrospectively analyzed. • Robot-assisted laparoscopic debulking surgery resulted in complete cytoreduction in all patients. • No perioperative complications were reported following robotic cytoreductive surgery. • A minimally invasive approach could reduce the complexity of successive surgeries for granulosa cell tumor relapse.

18 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JRJoline Roze
Joline Roze
JKJoachim Kutzera
Joachim Kutzera
WKWouter Koole
Wouter Koole
MAMargreet Center Ausems
Margreet Center Ausems
KEKristi Engelstad
Kristi Engelstad
GMGlen R. Monroe
Glen R. Monroe
Adult granulosa cell tumor (AGCT) is a rare ovarian cancer subtype, with a peak incidence around 50–55 years. Although AGCT can occur in specific syndromes, a genetic predisposition for AGCT has not been identified. The aim of this study is to identify a genetic variant in families with AGCT patients, potentially contributing to tumor evolution. We identified four families, each including two women diagnosed with AGCT. Whole-genome sequencing was performed to identify overlapping germline variants or affected genes. Familial relationship was evaluated using genealogy and genomic analyses. Patient characteristics, medical (family) history, and pedigrees were collected. Findings were compared to a reference group of 33 unrelated AGCT patients. Mean age at diagnosis was 38 years (range from 17 to 60) versus 51 years in the reference group, and seven of eight patients were premenopausal. In two families, three first degree relatives were diagnosed with breast cancer. Furthermore, polycystic ovary syndrome (PCOS) and subfertility was reported in three families. Predicted deleterious variants in PIK3C2G, BMP5, and LRP2 were identified. In conclusion, AGCTs occur in families and could potentially be hereditary. In these families, the age of AGCT diagnosis is lower and cases of breast cancer, PCOS, and subfertility are present. We could not identify an overlapping genetic variant or affected locus that may explain a genetic predisposition for AGCT.